Mechanisms of Action of Interleukin-2 Superkines [ 2018 - ]

Research Grant

Researchers: A/Pr Daniel Christ (Principal investigator) ,  A/Pr Cecile King ,  Prof Jonathan Sprent

Brief description Immunotherapy is emerging as one of the largest breakthroughs in cancer therapy in the last 30 years, due to the recent approval of the antibody therapeutics Ipilimumab (anti-CTLA4) and Pembrolizumab (anti-PD-1). This has greatly increased interest in other immune activating modalities, either for monotherapy, or in combination with antibody therapy. Here we propose to decipher molecular mechanisms that underpin the biological function of a new class of immune activating drugs (IL-2 superkines).

Funding Amount $725,585.00

Funding Scheme Project Grants

Notes Standard Project Grant